2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole | 146697-85-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole
• 英文别名: 2-[(2-iodoimidazol-1-yl)methoxy]ethyl-trimethylsilane
• CAS: 146697-85-0
• 化学式: C₉H₁₇IN₂OSi
• 分子量: 324.237
• InChiKey: NUNSVSJKGVVWFF-UHFFFAOYSA-N

物化性质

• 沸点：
  334.2±48.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 在 bis[μ-bromo(η³-prenyl)nickel] 作用下， 生成 Trimethyl-[2-[[2-(3-methylbut-2-enyl)imidazol-1-yl]methoxy]ethyl]silane
  参考文献：
  名称：

  Allylation of imidazoles. The beneficial effect of imidazole ligands on (.pi.-allyl)nickel coupling

  摘要：

  The coupling of (pi-allyl)nickel halide complexes with iodoimidazoles proceeds efficiently in toluene solution without the use of coordinating solvent or added ligand. Nickel-promoted allylation, and symmetrical coupling, of non-imidazole aryl halides is enhanced by using N-methylimidazole as an additive.

  DOI：

  10.1021/jo00057a006
• 作为产物：
  描述：

  1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 在 正丁基锂 、 碘 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.5h， 以74.1%的产率得到2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole
  参考文献：
  名称：

  裸组氨酸-丝氨酸模型：氢键对亲核性的影响和影响

  摘要：

  一个新的2-羟基烷（en / yn）咪唑家族被评估为L -lacOCA（一种环状O环）的开环反应的丝氨酸-组氨酸裸二联体模型。-羧酸酐。选择这些模型是为了阐明分子内氢键的含义并证实其对醇部分亲核性的影响，因为怀疑它发生在酶活性位点。尽管设计这些专用于在研究的开环反应过程中专门促进质子转移的初步步骤，但这些极简模型描述了相对于分离的片段而言可测量的反应性增加。已经开发了两种可靠的实验和理论方法来容易地监测稀溶液中分子内氢键的强度。结果显示，由于分子内氢键，折叠的构象异构体是最亲核的物种。

  DOI：

  10.1002/chem.201301275

文献信息

• [EN] FUSED AMINODIHYDROTHIAZINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINODIHYDROTHIAZINE FUSIONNÉS
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2012093148A1

  公开（公告）日：2012-07-12

  The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C1 -6 alkyl,optionally substituted by one to five halogen atoms; n is 0,1,2 or 3; Ar is phenyl or a 5-or 6-membered heteroaromatic group containing 1,2 or 3 N atoms,which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl,-CN,C1-6alkyl,C2-3alkenyl,C2-3alkynyl,C-6alkoxy,C3-6cycloalkoxy and pyrazine,where C1-6alkyl and C1-6alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease1 caused by Aβ and typified by Alzheimer-type dementia.

  本发明涉及一种公式（I）的融合氨基二氢噻唑衍生物：其中R是氢或C1-6烷基，可选地被一个至五个卤素原子取代；n是0、1、2或3；Ar是苯基或含1、2或3个N原子的5或6元杂芳基族，该Ar可选地被一个至三个选自卤素、羟基、-CN、C1-6烷基、C2-3烯基、C2-3炔基、C-6烷氧基、C3-6环烷氧基和吡嗪的取代基取代，其中C1-6烷基和C1-6烷氧基可选地被一个至三个卤素原子取代；以及药用可接受的盐；该化合物具有Aβ生成抑制效果或BACE1抑制效果，并且用作预防或治疗由Aβ引起的神经退行性疾病1的预防或治疗剂，该疾病以阿尔茨海默症型痴呆为典型。
• [EN] HEPATITIS C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'HÉPATITE C ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2012087833A1

  公开（公告）日：2012-06-28

  This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这份披露涉及：(a) 抑制HCV等化合物及其盐；(b) 用于制备这些化合物和盐的中间体；(c) 包含这些化合物和盐的组合物；(d) 制备这些中间体、化合物、盐和组合物的方法；(e) 使用这些化合物、盐和组合物的方法；以及(f) 包含这些化合物、盐和组合物的试剂盒。
• Fused Aminodihydrothiazine Derivatives
  申请人：Dimopoulos Paschalis

  公开号：US20140011802A1

  公开（公告）日：2014-01-09

  The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C 1-6 alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C 1-6 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C-6 alkoxy, C 3-6 cycloalkoxy and pyrazine, where C 1-6 alkyl and C 1-6 alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease 1 caused by Aβ and typified by Alzheimer-type dementia.

  本发明涉及一种公式（I）的融合氨基二氢噻唑衍生物：其中R是氢或C1-6烷基，可选地被一个至五个卤素原子取代；n是0、1、2或3；Ar是苯基或含1、2或3个N原子的5或6元杂芳族基团，其中Ar可选地被一个至三个选自卤素、羟基、—CN、C1-6烷基、C2-3烯基、C2-3炔基、C-6烷氧基、C3-6环烷氧基和吡嗪的取代基取代，其中C1-6烷基和C1-6烷氧基可选地被一个至三个卤素原子取代；以及药用可接受的盐；该化合物具有Aβ生成抑制效果或BACE1抑制效果，并且可用作预防或治疗由Aβ引起的神经退行性疾病1的预防或治疗剂，该疾病以阿尔茨海默症型痴呆为典型。
• [EN] SUBSTITUTED THIENYL-HYDROXAMIC ACIDS HAVING HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES DE THIENYLE SUBSTITUES PRESENTANT UNE ACTIVITE DE DEACETYLASE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2005014588A1

  公开（公告）日：2005-02-17

  A compound of formula (I): in which A represents optionally substituted monocyclic heteroaryl or phenyl B represents optionally substituted heteroaryl, aryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl X and Y, which may be the same or different, each independently represent -0-, -NR1-, CO-, -S02-, -SO-, -S-, -NR1CO-, -NR1S02-, -CONR1-, -SO2NR1-, -NR1CONR1 or X may be a direct bond when Y represents -NR1-, -NR1CO-, -NR1SO2-, -CONR1-, - SO2NR1- or -NR1CONRI- provided that R1 represents alkyl substituted by -OR2, -NR3R4, - NR4COR5, -NR4SO2R5, -CONR3R4 or -S02NR3R4 R1 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, or alkyl substituted by -OR2, -NR3R4, -NR4COR5, -NR4S02R5, -CONR3R4 or -S02NR3R4 R2 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl R3 represents H or alkyl R4 represents H, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl or cycloalkyl or NR3R4 represents a cyclic amine R5 represents alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl n represents 0-3 m represents 1-3 p represents 0-3 and corresponding N-oxides, pharmaceutically acceptable salts, solvates and prodrugs thereof; and use to treat a disease in which inhibition of histone deacetylase can prevent, inhibit or ameliorate the pathology and/or symptomatology of the disease.

  化合物的化学式（I）：其中A代表可选择取代的单环杂环芳基或苯基，B代表可选择取代的杂环芳基、芳基、芳基-融合-杂环烷基、杂环烷基-融合-环烷基、杂环烷基-融合-杂环烷基或芳基-融合-环烷基，X和Y，可以相同也可以不同，每个独立代表-0-、-NR1-、CO-、-SO2-、-SO-、-S-、-NR1CO-、-NR1SO2-、CONR1-、-SO2NR1-、-NR1CONR1或当Y代表-NR1-、-NR1CO-、-NR1SO2-、-CONR1-、-SO2NR1-或-NR1CONRI-时，X可以是直接键，条件是R1代表由-OR2、-NR3R4、NR4COR5、NR4SO2R5、CONR3R4或-S02NR3R4取代的烷基，R1代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基或由-OR2、-NR3R4、-NR4COR5、-NR4S02R5、-CONR3R4或-S02NR3R4取代的烷基，R2代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂环芳基、杂环烷基或环烷基，R3代表H或烷基，R4代表H、烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、环烷基烷基、芳基、杂环芳基、杂环烷基或环烷基，或NR3R4代表环胺，R5代表烷基、芳基、杂环芳基、环烷基、杂环烷基、芳基烷基、杂环芳基烷基、环烷基烷基、杂环烷基烷基，n代表0-3，m代表1-3，p代表0-3，以及相应的N-氧化物、药学上可接受的盐、溶剂合物和前药；以及用于治疗一种可以通过抑制组蛋白去乙酰化酶来预防、抑制或改善疾病的病理和/或症状的疾病。
• [EN] INDOLIN-2-ONE OR PYRROLO-PYRIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLIN-2-ONE OU DE PYRROLOPYRIDIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015197567A1

  公开（公告）日：2015-12-30

  The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar1 is phenyl or a five or six membered heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O, wherein the N-heteroatom in the heteroaryl group may be oxidized to N+-(O-); R1 is lower alkyl, halogen, cyano or cycloalkyl; Ar2 is a five or six membered heteroaryl group, containing one, two, three or four heteroatoms, selected from N, S or O, wherein the N-heteroatom in the heteroaryl group may be oxidized to N+-(O-), or is benzo[b]thiophenyl; R2 is hydrogen, lower alkyl, halogen, cyano, lower alkyl substituted by hydroxyl, lower alkyl substituted by halogen, lower alkyl substituted by amino, lower alkyl substituted by alkoxy, lower alkyl substituted by amide, or is cycloalkyl; X is CH or N; n is 1 or 2; m is 1 or 2; as well as with a pharmaceutically acceptable salt thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, epilepsy, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems.

  本发明涉及一般式（I）的2-氧代-2,3-二氢吲哚，其中Ar1为苯基或含有一个、两个或三个异原子（N、S或O）的五元或六元杂环芳基，其中杂环芳基中的N-异原子可以被氧化为N+-(O-)；R1为低碳基、卤素、氰基或环烷基；Ar2为含有一个、两个、三个或四个异原子（N、S或O）的五元或六元杂环芳基，其中杂环芳基中的N-异原子可以被氧化为N+-(O-)，或者为苯并[ｂ]噻吩基；R2为氢、低碳基、卤素、氰基、被羟基取代的低碳基、被卤素取代的低碳基、被氨基取代的低碳基、被烷氧基取代的低碳基、被酰胺取代的低碳基，或者为环烷基；X为CH或N；n为1或2；m为1或2；以及其药学上可接受的盐、消旋体混合物、或其对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗与精神病（精神病）、精神分裂症的阳性和阴性症状、物质滥用、酒精和药物成瘾、强迫症、认知障碍、躁郁症、情感障碍、重度抑郁症、治疗难治性抑郁症、焦虑障碍、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘人格障碍、神经退行性疾病、睡眠障碍、慢性疲劳综合征、僵硬、炎症性疾病、哮喘、亨廷顿病、注意力缺陷多动障碍、肌萎缩侧索硬化症、癫痫、关节炎作用、自身免疫疾病、病毒和真菌感染、心血管疾病、眼科学和炎症性视网膜疾病以及平衡问题相关的中枢神经系统疾病的治疗。